NCT04969835招募中1 期
A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients With Locally Advanced or Metastatic Selected Solid Tumours
Avacta Life Sciences Ltd18 个研究点 分布在 2 个国家目标入组 158 人开始时间: 2021年7月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 158
- 试验地点
- 18
- 主要终点
- Dose-limiting toxicities (DLTs)
研究概览
简要总结
This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.
详细描述
Phase 1a (Dose Escalation): The dose-escalation portion is designed to evaluate the safety, tolerability and MTD and/or RP2D of AVA6000, administered as monotherapy in two schedules: Day 1 of a 21-day cycle (Q3W schedule) and Day 1 of a 14-day cycle (Q2W schedule).
Phase 1b (Dose Expansion): The dose-expansion arm is based on review of data in the dose escalation phase, with AVA6000 administered at the recommended dose for expansion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has been fully informed about the study and has signed the Informed Consent Form.
- •Male or female patients, ≥ 18 years of age.
- •a) Phase 1a: patients with tumours reported to be FAP positive with histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic:
- •a. salivary gland, urothelial, ovarian, or breast carcinoma, who have either relapsed or progressed on SoC treatment or are intolerant or nonamenable to SoC treatment; OR b. soft-tissue sarcoma who: i. is treatment naïve in the locally advanced (unresectable) or metastatic setting and anthracycline naïve (any setting) and would otherwise be a candidate for doxorubicin hydrochloride treatment; OR ii. has received a total doxorubicin dose of < 150mg/m2 (any setting (< 2 cycles of 75 mg/m2 Q21 days) and has discontinued due to intolerance or toxicity related to doxorubicin
- •b) Phase 1b: patients with histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic tumour of one of the following types:
- •High grade soft tissue sarcoma: histologically proven locally advanced or metastatic, unresectable progressive or recurrent DDLS or UPS who have received 0 or 1 prior lines of therapy in the locally advanced or metastatic setting
- •SGC: Locally advanced or metastatic salivary gland confirmed by histopathology that cannot be completely resected by surgery who have received 0 or 2 prior lines of therapy in the locally advanced or metastatic setting. In addition, patients with adenoid cystic carcinoma subtypes must not have received prior cytotoxic therapy for locally advanced or metastatic disease. Adenoid cystic carcinoma subtype may be capped at 15 patients (assuming cohort of approximately 30 patients)
- •TNBC: Locally advanced or metastatic triple negative breast cancer confirmed by histopathology who have received any prior therapy in the locally advanced or metastatic setting. Patients must be BRCA wild-type.
- •In Phase 1b, patients must meet the following additional criteria:
- •Patients must demonstrate (as documented, per the investigator's assessment), radiological disease progression over the 6 months (±2 months) prior to screening. However, this requirement does not apply if the patient is newly diagnosed, recurrent or newly metastatic.
- •Patients must have measurable disease per RECIST.
- •Patients with high grade soft tissue sarcoma or salivary gland cancer must not have previously received an anthracycline-based therapy.
- •Patients with TNBC may receive up to 250mg/m2 of prior doxorubicin (or an equivalent anthracycline). Prior anthracycline based therapy must have been completed at least 6 months before the planned Cycle 1 Day 1 AVA6000 infusion. Prior anthracycline use must have been in the adjuvant or neoadjuvant setting only.
- •Patients must provide at least 1 tissue sample collection, either archival or fresh tissue (approximately 10 slides) unless the biopsy is medically not able to be performed or the principal investigator deems it is not medically feasible.
- •Has a life expectancy of ≥12 weeks, in the opinion of the investigator.
- •Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or
- •Has recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE grade ≤1 or returned to baseline, except alopecia and peripheral neuropathy, which can be up to CTCAE grade 2).
- •Has adequate haematological function (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose):
- •Absolute Neutrophil count (ANC) of ≥1.5 × 109 cells/L.
- •Haemoglobin ≥9.0 g/dL.
- •Platelet count of ≥75,000/µL.
- •International normalised ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 times the upper limit of normal (ULN).
- •Has adequate liver function:
- •Total bilirubin below ULN (except for patients with Gilbert's Syndrome who must have a total bilirubin <3 × ULN).
- •Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (in patients with liver metastases, <5 × ULN is allowed).
- •Alkaline phosphatase (ALP) <5 × ULN in patients with documented liver or bone metastases, or ALP < 2 × ULN in patients without documented metastases.
- •Has adequate renal function (creatinine clearance ≥50 mL/min by Cockcroft-Gault formula) or patients with normal plasmatic creatinine despite creatinine clearance < 50 mL/min as per Cockcroft-Gault formula are eligible for the study.
- •Women of childbearing potential (WOCBP) and women who have ≤ 2 years amenorrhea after start of menopause: has a negative serum pregnancy test within 7 days prior to Cycle 1 Day
- •Contraception requirements:
- •Female patients of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate <1% per year) during the treatment period and for at least 6 months after the last dose of study drug.
- •Male patients with female partners of childbearing potential must agree to using 2 acceptable methods of contraception (Pearl Index failure rate <1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug.
- •Male patients must agree to refrain from sperm donation during the treatment period and for at least 6 months after the last dose of study drug.
- •All patients should have peripheral veins or central line that are, in the opinion of the Investigator or delegate, suitable for peripheral or central intravenous infusion of AVA
- •The patient is willing and able to comply with the protocol, including any PK blood sampling requirements and agrees to return to hospital for follow-up visits and examinations.
排除标准
- •Has received trastuzumab within 7 months of the planned Cycle 1 Day 1 AVA6000 infusion.
- •Has received a prior total cumulative anthracycline dose of ≥ 350 mg/m2 doxorubicin (or equivalent anthracycline dose).
- •Has clinically significant or untreated central nervous system (CNS) metastases or leptomeningeal disease requiring treatment, as determined by the Investigator.
- •Patients who have any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal PSA) within 2 years of study entry.
- •Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol.
- •In the opinion of the investigator, has uncontrolled hypertension (systolic blood pressure >150 mm Hg and/or diastolic blood pressure >100 mm Hg), unstable angina, CHF (New York Heart Association (NYHA) Class >II), left ventricular ejection fraction (LVEF) <55% or the low limit of institutional normal limit (whichever is lower) by echocardiogram (ECHO), serious cardiac arrhythmia requiring treatment (exceptions include atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months prior to Cycle 1 Day 1, or history of uncontrolled cardiovascular disease or high-sensitivity troponin above normal at baseline (T or I).
- •Has a screening baseline mean corrected QTcF interval by Fridericia (QTcF) of >480 msec. Electrocardiograms (ECGs) will be evaluated locally at the investigator site. Has any clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec). Has any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, known family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval, a baseline resting bradycardia <45 beats/min or a baseline resting tachycardia of >100 beats/min.
- •HIV infection:
- •Patients with an AIDS-defining infection within 12 months of planned study Day
- •Patients on anti-retroviral treatment who are not established on anti-retroviral treatment for ≥4 weeks and who have a viral load > 400 copies/mL prior to study Day
- •Active hepatitis B (HBV) or hepatitis C (HCV) infection defined as:
- •Has a positive hepatitis B surface antigen (HBsAG) test at screening. Patients with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen [antiHBc] antibody test) are eligible.
- •Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- •Chronic HBV (HbSAg positive, undetectable or low HBV DNA and normal ALT).
- •Patients with active disease who have not on/initiated anti-retroviral treatment prior to study Day
- •Patients with untreated HCV infection or have not completed treatment for HCV infection.
- •Patients with treated HCV infection but with a HCV viral load above the level of quantification.
- •Has a severe infection (requiring iv treatment) within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalisation for complications of infection, bacteraemia, or severe pneumonia.
- •Has any other clinically significant active disease, metabolic dysfunction, physical examination finding, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug in the opinion of the investigator.
研究组 & 干预措施
AVA6000 Phase 1a Dose Escalation Q3W
Experimental
Patients in this arm will receive escalating doses of AVA6000 following a 3+3 design, Q3W until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
干预措施: AVA6000 (Drug)
AVA6000 Phase 1b Dose Expansion (dose identification)
Experimental
Dosing on this arm will occur at RDE -1 to identify the optimal biologic dose of AVA6000. Patients on this arm will receive AVA6000 until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, or death, whichever occurs first.
干预措施: AVA6000 (Drug)
AVA6000 Phase 1a Dose Escalation Q2W
Experimental
Patients in this arm will receive escalating doses of AVA6000 following a 3+3 design, Q2W until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, reaching maximum lifetime cumulative exposure to doxorubicin (or other anthracyclines), or death, whichever occurs first.
干预措施: AVA6000 (Drug)
AVA6000 Phase 1b Dose Expansion
Experimental
Patients in this arm will receive AVA6000 at the recommended dose for expansion, until disease progression, unacceptable toxicities, withdrawal from treatment for other reasons, or death, whichever occurs first.
干预措施: AVA6000 (Drug)
结局指标
主要结局
Dose-limiting toxicities (DLTs)
时间窗: Up to 28 days after the first dose of study therapy
Incidence and nature of DLTs
Adverse events (AEs)
时间窗: From Day 1 until up to 30 days after last dose of study drug.
Incidence and severity of treatment-emergent (TE) and treatment-related adverse events (TRAEs) and Seious Adverse Events (SAEs).
Laboratory abnormalities
时间窗: From Day 1 until up to 30 days after last dose of study drug.
Incidence of clinically significant laboratory abnormalities and changes in laboratory values (haematology, coagulation, serum chemistry and urinalysis).
Vital signs
时间窗: From Day 1 until up to 30 days after last dose of study drug.
Clinically significant changes in vital signs, physical examination findings, and ECG findings.
Cardiac safety
时间窗: From Day 1 until up to 30 days after last dose of study drug.
Clinically significant reduction in LVEF (fallen by \> 10% to below the lower level of institutional normal (as assessed by ECHO).
次要结局
- Maximum drug concentration (Cmax) of AVA6000 & Doxorubicin(Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation))
- Area under the curve (AUC) of AVA6000 & Doxorubicin(Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation))
- Elimination half-life (t1/2) of AVA6000 & Doxorubicin(Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation))
- Renal clearance (CLr) of AVA6000 & Doxorubicin(Cycle 1 and Cycle 2, 0-72 hours post dose (Dose Escalation))
- Objective response rate (ORR)(Up to one year)
- Duration of Response (DoR)(Up to one year)
- Progression-free-survival (PFS)(Up to one year)
- Overall survival (OS)(Up to one year)
研究者
研究点 (18)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced Solid TumorsRecurrent Solid TumorsMetastatic Solid TumorsNCT06031441Genentech, Inc.65
招募中
1 期
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing CancersLocally Advanced or Metastatic HER2-Expressing CancersNCT05356741Vir Biotechnology, Inc.645
招募中
1 期
A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid TumorsHER-2 Positive Advanced Solid TumorsNCT05957536D3 Bio (Wuxi) Co., Ltd128
已完成
1 期
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)CancerNCT04291079Scholar Rock, Inc.112
招募中
1 期
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid TumorsAdvanced Solid TumorNCT06750185BioNTech SE248